TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01590719
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m2 IV every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
Study: NCT01590719
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid 400 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
Study: NCT01590719
Drug: Levofolinic acid
Normalized name: Levofolinic acid
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If folinic acid is unavailable: levofolinic acid 200 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
Study: NCT01590719
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
Study: NCT04386304
Drug: (+)-Epicatechin
Normalized name: (+)-Epicatechin
DrugBank: Epicatechin (DB12039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-Epicatechin is a synthetic flavanol
Study: NCT02629718
Drug: NACT (Paclitaxel + Cisplatin or carboplatin)
Normalized name: Cisplatin
DrugBank: Lucinactant (DB04897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.
Study: NCT01317472
Drug: dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg dexlansoprazole QAM (1 hour AC) for 2 months
Study: NCT02187003
Drug: Rivipansel
Normalized name: Rivipansel
DrugBank: Rivipansel (DB12778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
Study: NCT01334177
Drug: TLR8 agonist VTX-2337
Normalized name: VTX-801
DrugBank: VTX-801 (DB17646)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT04144608
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1
Study: NCT00458055
Drug: Atorvastatin; Fenofibrate; Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
Study: NCT04385277
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04385277
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04385277
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or via enteral tube
Study: NCT04040088
Drug: Gallium Ga 68-DOTATATE
Normalized name: Gallium (Ga 68) dotatate
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04176198
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral JAK inhibitor
Study: NCT04176198
Drug: Momelotinib
Normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral JAK inhibitor
Study: NCT01354964
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02584686
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
Study: NCT00620451
Drug: larazotide acetate
Normalized name: Larazotide
DrugBank: Larazotide (DB05645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin capsule
Study: NCT02731586
Drug: Allogenic Mesenchymal stem cells
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogenic mesenchymal stem cells are introduced during placement of dental implants.
Study: NCT03464734
Drug: Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.
Study: NCT01285323
Drug: Reslizumab
Normalized name: Reslizumab
DrugBank: Reslizumab (DB06602)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
Study: NCT01709721
Drug: Hydromorphone Hydrochloride
Normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid for chronic pain
Study: NCT02475148
Drug: JNJ 54175446
Normalized name: JNJ-54175446
DrugBank: JNJ-54175446 (DB15358)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03915886
Drug: JNJ-0440
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-0440 tablets will be administered orally.
Study: NCT02630823
Drug: Paclitaxel (standard of care)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02630823
Drug: Carboplatin (standard of care)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02379156
Drug: Midodrine Hydrochloride
Normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
Study: NCT00133276
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
Study: NCT01748149
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib is supplied in 120-mg and 240-mg film-coated tablets packed in bottles for oral administration. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Dosing will not exceed the adult MTD of 960 mg twice a day (BID). Patients will be provided with a Medication Diary for vemurafenib, instructed in its use, and asked to bring the diary with them to each appointment.~Treatment will be administered on an outpatient basis. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Regardless of cohort, patients will self-administer vemurafenib BID at the assigned dose level. Patients will be instructed to hold their dose of vemurafenib for PK or surgery.
Study: NCT01592734
Drug: Polyethylene glycol with electrolytes
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.~Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days.
Study: NCT04421963
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg olaparib (2×150 mg tablets) twice daily
Study: NCT00736541
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
Study: NCT02736448
Drug: Lu-PRRT
Normalized name: LU-31130
DrugBank: LU-31130 (DB05828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
Study: NCT03679611
Drug: Sugammadex Sodium
Normalized name: Sugammadex sodium
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex is a FDA approved newer NMBD reversal agent. But does not use in standard of care in most of institutions This study is designed to compare the impact of reversal of neuromuscular blockade with sugammadex vs. neostigmine on discharge time from the operating room in obese patients with OSA undergoing bariatric surgery
Study: NCT03679611
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: neostigmine is a FDA approved NMBD reversal drug, uses as standard care drug in most of the institutions. neostigmine use as active comparator to compare with investigational drug Sugammadex in the study.
Study: NCT04540627
Drug: Palivizumab
Normalized name: palivizumab
DrugBank: Palivizumab (DB00110)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
Study: NCT03044613
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240mg or 1 mg/kg administered IV
Study: NCT03044613
Drug: Relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg administered IV
Study: NCT03044613
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard care dose
Study: NCT03044613
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: standard care dose
Study: NCT03169764
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (SP-4-2)-diamminedichloroplatinum(II)
Study: NCT03169764
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03169764
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
Study: NCT03169764
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study: NCT03169764
Drug: Lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3-acid ethyl esters
Study: NCT03512314
Drug: Tadekinig alfa
Normalized name: Tadekinig alfa
DrugBank: Tadekinig alfa (DB14858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label, 26 weeks on Tadekinig alfa treatment.
Study: NCT03391466
Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-containing salvage chemotherapy (R-ICE, R-DHAP, R-ESHAP, or R-GDP as selected by treating investigator) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
Study: NCT03391466
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT03821246
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03821246
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03821246
Drug: Etrumadenant
Normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Orally
Study: NCT02502591
Drug: Pudendal Nerve Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
Study: NCT03764137
Drug: [89Zr]Panitumumab PET-MRI
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
Study: NCT02651324
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03822637
Drug: n-acetylcystine + albuterol
Normalized name: Albuterol
DrugBank: Cystine (DB00138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC is a mucolytic drug and Albuterol is a bronchodilator.
Study: NCT03822637
Drug: 0.9% saline + albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is a placebo agent and Albuterol is a bronchodilator.
Study: NCT04286607
Drug: Topical roflumilast
Normalized name: roflumilast Topical Product
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Active treatment
Study: NCT01974245
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 IU/week for 12 weeks
Study: NCT03785873
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT03785873
Drug: Nanoliposomal-Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT03785873
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT03442413
Drug: I.V. Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in our study will receive intravenous nicotine at the adaptation session and each of the PET scans, close to the amount of nicotine absorbed from smoking 1/10 cigarette.
Study: NCT03946527
Drug: Lanreotide
Normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
Study: NCT04614363
Drug: 68Ga-PSMA
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.
Study: NCT02992288
Drug: Neladenoson bialanate (BAY1067197)
Normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg orally once daily for 20 weeks
Study: NCT02992288
Drug: Neladenoson bialanate (BAY1067197)
Normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg orally once daily for 20 weeks
Study: NCT02992288
Drug: Neladenoson bialanate (BAY1067197)
Normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg orally once daily for 20 weeks
Study: NCT02992288
Drug: Neladenoson bialanate (BAY1067197)
Normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg orally once daily for 20 weeks
Study: NCT02992288
Drug: Neladenoson bialanate (BAY1067197)
Normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg orally once daily for 20 weeks
Study: NCT00023777
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
Study: NCT00023777
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ind and consol: 45 mg/m2/d continuous IV days 1-3
Study: NCT00456846
Drug: ABI-007
Normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest
Study: NCT03505762
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03505762
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02560805
Drug: Sodium Nitroprusside (SNP)
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
Study: NCT02560805
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
Study: NCT02560805
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan will be administered as 25 mg taken orally, once a day for to 8 to 14 weeks.
Study: NCT02560805
Drug: Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol will be administered as 25 mg taken orally, once a day for to 8 to 14 weeks.
Study: NCT03444701
Drug: E7130
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose of 25 μg/m\^2 on Day 1 and Day 15 of Cycle 1.
Study: NCT03444701
Drug: E7130
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.
Study: NCT04347122
Drug: Tranexamic Acid (TXA)
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.
Study: NCT02856568
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02856568
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02856568
Drug: Ricolinostat
Normalized name: Ricolinostat
DrugBank: Ricolinostat (DB12376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01684930
Drug: Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
Study: NCT02345265
Drug: Cediranib Maleate
Normalized name: maleate
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02345265
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00003042
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003042
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003042
Drug: mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003042
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00003042
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04214990
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily aspirin 100 mg for 5 years
Study: NCT05581758
Drug: AMG 510
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT03793478
Drug: Quizartinib
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28
Study: NCT03793478
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)